Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2004;94:1227-1234
Published online before print March 25, 2004, doi: 10.1161/01.RES.0000126567.75232.46
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
94/9/1227    most recent
01.RES.0000126567.75232.46v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cao, D. J.
Right arrow Articles by Colman, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cao, D. J.
Right arrow Articles by Colman, R. W.
Related Collections
Right arrow Other Vascular biology
Right arrow Angiogenesis
Right arrow Apoptosis
(Circulation Research. 2004;94:1227.)
© 2004 American Heart Association, Inc.


Molecular Medicine

Urokinase-Type Plasminogen Activator Receptor Is Involved in Mediating the Apoptotic Effect of Cleaved High Molecular Weight Kininogen in Human Endothelial Cells

Dian J. Cao, Yan-Lin Guo, Robert W. Colman

From the Sol Sherry Thrombosis Research Center (D.J.C., Y.-L.G., R.W.C.), Department of Medicine (R.W.C.), Temple University School of Medicine, Philadelphia, Pa.

Correspondence to Robert W. Colman, MD, Temple University School of Medicine, 3400 N Broad St, Philadelphia, PA 19140. E-mail colmanr{at}temple.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Cleaved high molecular weight kininogen (HKa) has been shown to inhibit in vivo neovascularization and induce apoptosis of endothelial cells. We have shown that HKa-induced apoptosis correlated with its antiadhesive effect and was regulated by extracellular matrix (ECM) proteins. In this study, we identified the urokinase-type plasminogen activator receptor (uPAR) as a target of HKa activity at the endothelial cell surface. Anti-uPAR antibodies blocked the apoptotic effect of HKa. Further studies revealed that uPAR formed a signaling complex containing integrin {alpha}vß3 or {alpha}5ß1, caveolin, and Src kinase Yes in endothelial cells. HKa physically disrupted the formation of this complex in a manner that paralleled its apoptotic effect. For the first time, our results provide a mechanistic explanation for the previous observation that HKa selectively induces apoptosis of endothelial cells grown on vitronectin, but not cells grown on fibronectin. These data also resolve the controversial role of uPAR in mediating the apoptotic and antiadhesive activities of HKa.


Key Words: urokinase-type plasminogen activator receptor • high molecular weight kininogen • endothelial cells • apoptosis • angiogenesis


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Angiogenesis, the formation of new capillaries from existing blood vessels, is a cellular event crucial for both physiological and pathological processes such as embryogenesis and cancer development,1 respectively. A positive balance in favor of angiogenic factors leads to new blood vessel formation, whereas the predominance of angiogenic inhibitors will switch the equilibrium to vessel quiescence or vessel regression.2–5

High molecular weight kininogen (HK) is a plasma protein that was first identified as a precursor of the bioactive peptide bradykinin. We now recognize that HK is a multifunctional protein that plays important roles in many pathophysiological processes, such as fibrinolysis, thrombosis, and inflammation.6 HK is a 120-kDa single-chain glycoprotein consisting of six domains (designated as D1 to D6, respectively) with each having distinct functions.7 After proteolytic cleavage of HK by kallikrein and release of bradykinin contained within D4, the remaining portion of the molecule, HKa, undergoes major conformational changes that lead to a greater surface exposure of the D5 region. As a result, HKa acquires new properties. In comparison with HK, HKa shows an increased antiadhesive effect due to domain rearrangements.8,9 HK specifically and reversibly binds to endothelial cells in a Zn2+-dependent manner. Thus, the endothelial cell surface is an important site for the generation of both bradykinin and HKa, each of which regulates the functions of endothelial cells. Although the involvement of bradykinin in the regulation of many physiological and pathophysiological processes has been intensively studied, the functional implications of the generation of HKa are incompletely understood. Recent studies from our laboratory and other investigators indicate that HKa may act as a naturally occurring angiogenic inhibitor.10,11 Interestingly, it has recently been shown that bradykinin stimulates angiogenesis.12,13 Therefore, HK is a precursor of both an angiogenic stimulator (bradykinin) and an angiogenic inhibitor (HKa).

After our initial discovery of HKa and its domain 5 as angiogenic inhibitors,10 we have further shown that HKa inhibits human umbilical vein endothelial cell (HUVEC) proliferation and induces apoptosis,14,15 which together may represent a critical step of their antiangiogenic activity. In our most recent study,16 we demonstrated that the apoptotic effect of HKa is related to its antiadhesive activity and its ability to disrupt signaling pathways required for cell adhesion. Furthermore, the apoptotic effect of HKa is highly regulated by interactions with different extracellular matrix proteins; it strongly induces apoptosis of endothelial cells grown on vitronectin (Vn) but has no significant effect on the viability of cells grown on fibronectin (Fn).16,17 However, a fundamentally important unanswered question is how the effects of HKa and D5 are mediated at the endothelial cell membrane.

In the present study, we provide substantial evidence to support the hypothesis that urokinase-type plasminogen activator receptor (uPAR), a glycophosphatidylinositol (GPI)-anchored cell surface protein that plays an important role in cell adhesion and signal transduction,18 is a target of HKa action at the endothelial cell surface. We have previously shown that HKa physically binds to uPAR in endothelial cells.19 We now demonstrate the specific downstream events: HKa disrupts the signaling complex by decreasing uPAR-integrin and/or uPAR-caveolin association. Thus, this study constitutes the first report that provides a mechanistic explanation for the previous observation that HKa selectively induces apoptosis of endothelial cells grown on Vn but not cells grown on Fn.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Apoptosis Analysis
Apoptotic cell death induced by HKa has been characterized by a combination of DNA and nuclear fragmentation and annexin V staining, which have been described in our previous studies.14,20 The present study used nuclear fragmentation analysis with Hoechst 33285 staining to identify apoptotic cells at the cellular level. HUVECs were seeded on Vn- (0.053 mmol/L) or Fn- (0.023 mmol/L) coated coverslips in EGM. After the cells attached to the coverslips, the medium was changed to EBM (EGM minus growth factors and FBS) plus 0.59 µmol/L bFGF in the presence or absence of 100 nmol/L HKa. P-D2D3 (the anti-serum against the D2 and D3 domains of uPAR) or the same amount of control preimmune serum (PIS) was added to the medium at a concentration of 30 µL/mL. After incubation for 48 hours, cells were analyzed for apoptosis according to methods described previously.14

Apoptosis was quantified by a Cell Titer Aqueous kit (Promega) as described previously.14 The cells were incubated with bFGF (0.59 µmol/L) in the presence or absence of 100 nmol/L HKa. Monoclonal anti-uPAR antibodies (E33, E174, and E180) or control mouse IgG, P-D2D3, or rabbit PIS, were added to the medium at different concentrations as indicated. Apoptosis assay was also performed using anti-cytokeratin-1 and anti-gC1qR (clone 74.5.2) antibodies at concentrations indicated.

Immunoprecipitation and Immunoblot Analysis
HUVECs were plated on cell culture dishes coated with Vn or Fn in EGM. After the cells attached to the dishes, the culture medium was changed to EBM plus 0.59 µmol/L bFGF. Cells were treated with or without 100 nmol/L HKa for 25 to 30 hours at 37°C. After treatment, the cells attached to the dishes and those from the medium were collected and lysed with modified M-per mammalian cell protein extraction buffer (Pierce) containing 5 mmol/L Ca2+, 2 mmol/L Mg2+, and protease inhibitor cocktail (Chemicon International). After incubation for 10 minutes at room temperature, cell lysates were collected by centrifugation at 21 000g for 15 minutes at 4°C.

The complex formation of uPAR with other signaling molecules was determined by immunoprecipitation (IP) according to the methods described by Wei et al21 with some modifications. Cell lysate was incubated with antibodies to {alpha}vß3, {alpha}5ß1, uPAR, or PECAM-1 followed by incubation of protein A/G beads. The immunoprecipitates were subjected to SDS-PAGE under reduced conditions, and immunoblot analysis was performed as described.14

For a description of other methods, see the expanded Materials and Methods available in the online data supplement at http://circres.ahajournals.org.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Anti-uPAR Antibodies Block Apoptotic Effect of HKa in HUVECs
A previous investigation from this laboratory has shown that HKa directly binds to uPAR because an anti-uPAR D2D3 (domains 2 and 3) antibody blocked the binding of HKa to endothelial cells.19 We postulated that uPAR may be involved in mediating the apoptotic effect of HKa. To test this hypothesis, we used P-D2D3, an antibody raised against the D2D3 region of uPAR, to examine if this antibody can block the apoptotic effect of HKa. HUVECs were cultured on Vn or Fn and incubated with HKa in the presence or absence of P-D2D3. We choose to use 100 nmol/L HKa based on our previous report.16 As shown in Figure 1, bFGF sustained the viability of HUVECs within a 48-hour incubation period, with cells displaying normal nuclei morphology (Figure 1A, bFGF). HKa caused condensation/fragmentation of nuclei (apoptotic nuclei) in many cells grown on Vn (Figure 1A, bFGF+HKa). The effect of HKa was reversed by P-D2D3 (Figure 1A, bFGF+HKa+P-D2D3), whereas preimmune serum (PIS) had no effect (Figure 1A, bFGF+HKa+PIS). Consistent with our previous observation that HKa did not induce apoptosis of HUVECs grown on Fn,16 neither HKa nor P-D2D3 and PIS exhibited an apparent effect on cell viability when cells were grown on Fn (Figure 1B). P-D2D3 alone did not show apparent effect on the viability of cells grown on Vn and Fn (data not shown).



View larger version (46K):
[in this window]
[in a new window]
 
Figure 1. The anti-uPAR D2D3 antibody blocks apoptosis induced by HKa. HUVECs grown on Vn (A) or Fn (B) were treated with 100 nmol/L HKa in the absence or presence of P-D2D3 (30 µL/mL) (bFGF+HKa, bFGF+HKa+P-D2D3, respectively). After 48 hours of treatment, cells were stained with Hoechst 33258. Typical nuclear morphology of apoptotic cells is indicated with white arrows.

We have previously shown that apoptosis of endothelial cells induced by HKa was largely due to its antiadhesive effect.16 As a result, most of late apoptotic cells are released into the medium. The number of viable cells still attached to the culture plate after treatment, which is inversely related to the number of apoptotic cells in the medium, was quantified to reflect HKa-induced apoptosis. When cells were grown on Vn, viable cells left in the HKa-treated cells was 30% of the control (in the absence of HKa), representing 70% of the cells death from apoptosis. The apoptotic effect of HKa under this condition was defined as 100%. As shown in Figure 2A, the apoptotic effect of HKa was significantly inhibited by antibody P-D2D3 in a concentration-dependent manner, whereas PIS had no effect (Figure 2A). The same experiments were performed using three monoclonal anti-uPAR antibodies (E33, E174, and E180) at a concentration of 10 µg/mL. All of these antibodies significantly blocked the apoptotic effect of HKa but with different potency (Figure 2B). Because both the polyclonal and monoclonal antibodies were made against D2D3 domains of uPAR, it is likely the D2D3 domains of uPAR are the targeted regions by HKa. A nonrelevant mouse IgG (m-IgG) as a control for the monoclonal antibodies did not affect the effect of HKa (Figure 2B). Similar experiments were also performed using anti-cytokeratin-1 and anti-gC1qR antibodies (Figure 2A, Ab1 and Ab2, respectively). The results showed that the apoptotic effect of HKa was blocked by anti-cytokeratin-1, but not by anti-gC1qR antibodies (Figure 2A). Consistent with the results presented in Figure 1B, HKa did not induce apoptosis of endothelial cells grown on Fn (data not shown).



View larger version (27K):
[in this window]
[in a new window]
 
Figure 2. Effect of anti-uPAR antibodies on HKa-induced HUVEC apoptosis. HUVECs were treated with or without 100 nmol/L HKa for 48 hours. HKa-treated cells were incubated with increasing amounts (0, 10, and 30 µL/mL) of P-D2D3 (A) or with E33, E174, and E180 at a concentration of 10 µg/mL (B). Same amount of PIS was used as controls for P-D2D3. Nonspecific mouse IgG (m-IgG) served as controls for E33, E174, and E180. Similarly, HKa-treated cells were incubated with anti-cytokeratin-1 (Ab1, 30 µg/mL) or anti-gC1qR (Ab2, 10 µg/mL) antibodies (A). Apoptosis in bFGF+HKa-treated groups is expressed as 100% (control, C). Results are mean±SEM from 3 to 6 individual experiments. *P<0.01 vs control.

uPAR Forms Complexes With Integrins and Caveolin
Because uPAR is a GPI-anchored cell surface protein, the signal received by uPAR must be transduced through its interaction with other signaling molecules. uPAR has been shown to interact with integrins and caveolin in other cell types.21–24 We then tested whether this is the case in endothelial cells. Cell lysates from HUVECs were incubated with anti-{alpha}vß3 or anti-{alpha}5ß1 antibodies. As shown in Figures 3A and 3B, both uPAR and caveolin were detected in the samples precipitated either by anti-{alpha}vß3 or by anti-{alpha}5ß1 antibodies, indicating that uPAR, {alpha}vß3, or {alpha}5ß1, and caveolin form a complex in HUVECs grown on gelatin (Figure 3A, Gel), Vn (Figure 3B, Vn), or Fn (Figure 3B, Fn). The presence of integrin {alpha}vß3 and {alpha}5ß1 was confirmed by probing the immunoprecipitates with anti-integrin {alpha}v or ß1 subunits, respectively. Further results showed that the complex precipitated with anti-{alpha}5ß1 antibody contained {alpha}v subunit (Figure 3C), whereas the complex precipitated with anti-uPAR antibody contained both {alpha}v and ß1 subunits (Figure 3D). In a control experiment, cell lysate was incubated with anti-PECAM-1 antibodies. The immunoprecipitate contained abundant PECAM-1, as expected, but not uPAR (Figure 3E). These results indicate that uPAR form a complex that contains specific signaling components.



View larger version (29K):
[in this window]
[in a new window]
 
Figure 3. uPAR forms complexes with integrins {alpha}vß3, {alpha}5ß1, and caveolin. A, Cell lysate from HUVECs grown on Gel was immunoprecipitated with anti-{alpha}vß3 or anti-{alpha}5ß1 antibodies (IP). Components of the immunoprecipitates were probed with the indicated antibodies (IB). B, Same experiments as described in A were performed using cell lysates from cells grown on Vn or Fn. C, Cell lysates from cells grown on Gel were immunoprecipitated with anti-{alpha}5ß1 antibodies. Immunoprecipitates were probed for ß1 or {alpha}v subunit. D, Cell lysates from cells grown on Gel were precipitated with anti-uPAR antibodies (E33) and then the immunoprecipitates were probed for uPAR and integrin {alpha}v or ß1 subunits. E, Cell lysate prepared as described above was immunoprecipitated with an anti–PECAM-1 antibody and probed with antibodies against PECAM-1 and uPAR.

HKa Disrupts the Complex Formation Among uPAR, Integrin, and Caveolin
We have shown that HKa-induced apoptosis in endothelial cells is ECM protein dependent.16 HKa exhibited a maximum apoptotic effect on HUVECs grown on Vn, whereas its effect on cells grown on Fn was minimal. We further analyzed the effect of HKa on complexes formed by uPAR, {alpha}vß3/{alpha}5ß1, and caveolin in HUVECs grown on Vn and Fn. As shown in Figure 4A, HKa treatment reduced the amount of uPAR associated with {alpha}vß3 to a similar extent in cells grown on Vn and Fn; however, the amount of caveolin in the complex was markedly reduced in cells grown on Vn compared with cells grown on Fn (Figure 4A). Figures 4B and 4C quantified the relative amount of uPAR and caveolin associated with {alpha}vß3 determined by densitometry from three independent experiments. In Figure 4G, total cell lysates from control and HKa-treated groups before IP were probed with anti-caveolin and anti-uPAR antibodies. No significant differences in total amount of these proteins were detected among groups.



View larger version (46K):
[in this window]
[in a new window]
 
Figure 4. HKa dissociates uPAR and caveolin from integrin {alpha}vß3 or {alpha}5ß1 in cells grown on Vn and Fn. Cell lysates from HUVECs grown on Vn or Fn were precipitated with anti-{alpha}vß3 (A) or anti-{alpha}5ß1 antibodies (D), and the immunoprecipitates were probed with the antibodies as indicated. Total cell lysates before IP were analyzed for actin to show equal amount of protein used for IP experiments. B, C, E, and F, Summarized results of the relative amount of uPAR and caveolin in the complexes quantified from 3 individual experiments by densitometry and are presented using relative units normalized to control (without HKa treatment). G, Cell lysates from control and HKa-treated groups before IP were subjected to SDS-PAGE and probed with anti-caveolin and anti-uPAR antibodies. *P<0.05 vs control.

In parallel experiments, cell lysates were incubated with anti-{alpha}5ß1 antibodies as shown in Figure 4D. Interestingly, in cells cultured on Vn, HKa almost completely disassociated uPAR and caveolin from the complex precipitated with anti-{alpha}5ß1 antibody. On the other hand, when cells were grown on Fn, although HKa also disassociates uPAR from {alpha}5ß1 to some extent, it had no apparent effect on the association of caveolin with {alpha}5ß1 (Figures 4D through 4F). Cell lysates before IP were also analyzed for actin. As shown in Figure 4A and 4D, the amount of actin was similar among groups, indicating that the same amount of proteins was used for IP experiments. HKa disassociates uPAR with a higher potency from the complex formed by {alpha}5ß1 than it does from the complex formed with {alpha}vß3. HKa almost completely dissociates caveolin from both complexes in cells grown on Vn, indicating that disassociation of caveolin from the complex may play an important role in mediating the apoptotic and antiadhesive effects of HKa.

HKa Disrupts the Association of Src Kinase Yes From Integrin {alpha}vß3-Assembled Complex
Src family tyrosine kinases are nonreceptor tyrosine kinases that have been reported to interact with caveolin and integrins.23 Therefore, Src kinases are downstream effectors of integrin pathways in some cells.24,25 To test whether this is the case in endothelial cells, we chose to examine the presence of Yes as a representative of this kinase family. The immunocomplex precipitated by anti-{alpha}vß3 antibodies was probed with an anti-Yes antibody. Results shown in Figure 5A demonstrate that Yes was associated with {alpha}vß3 in endothelial cells, and that HKa caused almost complete loss of Yes from the {alpha}vß3 complex in cells grown on Vn, and to a lesser extent, in cells grown on Fn. In Figure 5B, a dose-response was performed regarding HKa-induced dissociation of Yes from the {alpha}vß3 complex in cells grown on Vn. These data suggest that the HKa not only disrupts the uPAR-integrin-caveolin signal complex formation at the cell membrane, it also effectively blocks signal transduction at downstream uPAR-integrin signaling pathways.



View larger version (34K):
[in this window]
[in a new window]
 
Figure 5. Src kinase Yes is associated with {alpha}vß3-uPAR-caveolin complex. A, Cell lysates prepared as described in Figure 4 were precipitated with anti-{alpha}vß3, and the resolved precipitates were probed with anti-{alpha}v and anti-Yes antibodies. B, HKa dose-response for the relative amount of Yes in the {alpha}vß3-uPAR-caveolin complex in cells grown on Vn.

uPAR Mediates HUVEC Adhesion to Vn
Given the fact that Vn is a well-known adhesion molecule for many types of cells including endothelial cells and that uPAR is well-recognized adhesion receptor for Vn in epithelial cells26 and leukocytes,27 the contribution of uPAR-mediated cell adhesion in endothelial cells is not clear. A report by Kanse et al28 indicated that uPAR is a major Vn binding protein. Surprisingly, uPAR-mediated cell adhesion was not detected in that study, an observation made from the indirect experiments using uPA as an uPAR ligand. However, it has been reported that uPAR mediates several cellular processes in a ligand (uPA)-independent manner.29 In an effort to resolve this uncertainty in endothelial cells, we treated cells with PI-PLC to cleave uPAR from the cell surface. The result, as shown in Figure 6, demonstrated that uPAR is responsible for 50% of HUVEC binding to Vn under the conditions tested. PI-PLC treatment, however, was not able to significantly affect the cell adhesion on Fn (Figure 6).



View larger version (17K):
[in this window]
[in a new window]
 
Figure 6. PI-PLC treatment reduced HUVEC adhesion to immobilized Vn and Fn. HUVECs treated with or without PI-PLC were seeded on Vn- or Fn-coated 96-well plates in triplicates followed by further incubation at 37°C for 30 minutes. After washing, the attached cells were fixed, stained with 0.5% crystal violet, and counted (6 fields per well). Cell number in control group (without PI-PLC treatment) was set as 100%. *P<0.05 vs control.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
HKa and its domain 5 (D5) have been shown to inhibit in vivo neovascularization in different animal models independently by this group10 and other investigators.11 However, the signaling mechanism that mediates their activity has not been elucidated. For the first time, we demonstrate that uPAR, an adhesion and signaling receptor, is a target of HKa action at the endothelial cell surface. Together with our previously published results,16 we demonstrate that HKa can disrupt the uPAR-{alpha}vß3/{alpha}5ß1-caveolin-yes-FAK-paxillin signaling pathway at each level of these signaling components. The results described in this study represent major progress in our effort to characterize HKa as an angiogenic inhibitor.

Several endothelial cell membrane proteins that interact with HK or HKa have been identified, including uPAR,19 the receptor for the globular head of C1q (gC1qR),30 and cytokeratin-1.30,31 It has been shown that cytokeratin-1 binds to both uPAR and gC1qR, but uPAR and gC1qR do not bind to each other.32 A recent study revealed that uPAR and cytokeratin-1 colocalize on endothelial cells and may form a receptor complex that mediates HK binding and the subsequent release of bradykinin.33 Among these proteins, uPAR, a GPI-anchored cell surface protein that contains three domains, is particularly relevant to cell adhesion and angiogenesis.18,34 Although initially identified as a receptor for urokinase plasminogen activator (uPA) to localize proteolytic activity on the cell surface during invasion,18,35 it is now known that uPAR also interacts with integrins at the cell membrane and binds to Vn in a uPA-dependent or independently manner.29 Vn is a major provisional ECM protein and plays an important role in angiogenesis during vascular remodeling and vessel repair.36 As a result of these interactions, uPAR acts as an adhesion receptor for Vn and transduces signals through integrin pathways.37

The initial notion that uPAR may mediate the apoptotic effect of HKa came from our previous study,19 which showed that HKa binds to endothelial cells through D2 and D3 of uPAR. The binding of HKa to endothelial cells can be completely blocked by an anti-uPAR D2 and D3 antibody, or by soluble recombinant uPAR.19 We, therefore, postulated that uPAR could be a logical target of HKa for its antiangiogenic activity. However, a recent study11 by Zhang et al indicated that none of the three antibodies against gC1qR, cytokeratin-1, or uPAR, which had previously been shown to inhibit HK or HKa binding to endothelial cells,19,30,31 affected the ability of HKa to induce apoptosis of endothelial cells. Our examination of the other two antibodies was demonstrated in Figure 2A. We were able to show that the anti-cytokeratin-1 antibody blocked the apoptotic effect of HKa on cells grown on Vn. As demonstrated by Joseph et al,32 cytokeratin-1 forms a complex with uPAR. Thus, the antibody against cytokeratin-1 could interfere with the association of HKa with uPAR-cytokeratin-1 complex and block the apoptotic effect of HKa. We also performed similar experiments using the anti-gC1qR antibody. We were unable to detect any blocking effect of this antibody to HKa-induced cell apoptosis on Vn. This finding indicates that uPAR plays more significant role under our experimental condition in which Vn is used as a coating ECM protein and consistent with previous finding that gC1qR does not form a complex with uPAR.32

Although the results from Zhang’s report argue against a role of uPAR in mediating the effect of HKa,11 in collaboration with Chavakis et al,27 we were able to show that HKa or D5 completely inhibited uPAR-mediated cell adhesion to Vn, thereby promoting cell detachment in U937 and uPAR-transfected BAF-3 cells. HKa or D5 failed to elicit a similar effect when cells were plated on Fn under the same conditions.27 We recently demonstrated in endothelial cells that HKa and D5 exhibit dramatic apoptotic activity on the cells grown on Vn, but its effect on cells grown on Fn was minimal.16 These studies suggested that the effect of HKa and D5 depends on the nature of ECM proteins, and that uPAR could be a target of HKa but may require the presence of Vn. We now provide strong evidence to support this hypothesis. First, four different anti-uPAR D2/D3 antibodies blocked the apoptotic effect of HKa on cells grown on Vn but not on Fn. Secondly, we demonstrated that uPAR formed a signaling complex with {alpha}vß3/{alpha}5ß1, caveolin, and Yes kinase. Although this phenomenon and the functional implication of this signaling cluster formation has been studied in other cell systems,21–24 it has not been reported in endothelial cells in previous studies. The most important finding of these experiments, however, is that HKa could disrupt the association of uPAR with these signaling components in a manner that parallels its antiadhesive and apoptotic effects. Although HKa also disrupted uPAR-{alpha}5ß1/{alpha}vß3 complex formation in cells on Fn to some extent, it did not result in cell detachment or apoptosis. This result could be explained by the fact that Fn is the ligand for at least 12 integrins, whereas Vn is a ligand for only four ({alpha}vß1, {alpha}vß3, {alpha}vß5, and {alpha}IIbß3).38 The larger number of integrins binding to Fn may contribute to the resistance of cells to the antiadhesive effect of HKa on cells grown on Fn. This hypothesis may not only explain the ECM protein dependency of antiadhesive and apoptotic effect of HKa but also the failure of the anti-uPAR antibodies to block the apoptotic effect of HKa reported by Zhang et al,11 where the experiment was conducted in cells grown on gelatin (in the absence of Vn).

We previously demonstrated that HKa directly binds to Vn.27 The present study extends that report by demonstrating specific downstream events. The hypothesis that HKa binds to Vn and subsequently blocks cell adhesion to Vn does not contradict the results presented in the current study. Whether the upstream event is HKa binding to Vn and/or HKa competing with Vn for binding to uPAR, the downstream event might be the same. These two steps will finally lead to interference of uPAR/integrin interaction and subsequently endothelial cell apoptosis

Because {alpha}5ß1 is not a ligand of Vn, we are not certain how HKa treatment also caused disassociation of uPAR and caveolin from {alpha}5ß1 complex. Because uPAR can form complexes with several integrins, including {alpha}3ß1 and {alpha}5ß1, and {alpha}vß3,21 it is possible that these complexes may consist of more than one integrins. As a result of these associations, the integrins can modulate each other’s function. For example, Chapman and colleagues21 have shown that, in 293 cells, uPAR complex with {alpha}3ß1, promoting direct (to Vn) and indirect (to Fn) cell adhesion through modulating the function of {alpha}5ß1 and {alpha}2ß1. Cross-talk between {alpha}vß3 and {alpha}5ß1 is also implicated in the regulation of cell migration.39 We speculate that collaboration between {alpha}vß3 and {alpha}5ß1 may also occur in endothelial cells. Indeed, the {alpha}v subunit was detected in the uPAR-{alpha}5ß1-complex. Therefore, HKa-induced disruption of uPAR-{alpha}5ß1-caveolin may indirectly affect Vn-{alpha}vß3 interaction.

In our recent study,16 we have shown that the antiadhesive effect and the apoptotic effect of HKa are associated with the inhibition of activation of focal adhesion kinase (FAK) and paxillin, two important signal molecules required for cell adhesion and cell survival.40,41 We can now establish a signaling cascade, Vn-uPAR-{alpha}vß3-caveolin-Src-FAK-paxillin, that mediates adhesion, proliferation, and survival of endothelial cells. HKa disrupts this signaling cascade by at least two mechanisms: first, through its direct binding to the somatomedin B (SMB) domain of Vn, HKa prevents the binding of Vn to integrin {alpha}vß327; and secondly, HKa directly binds to the D2 and D3 domains of uPAR through its D5 region, thus preventing the binding of Vn to uPAR and its interaction with integrins as well as other signaling molecules, such as caveolin. As a result of these interactions of HKa with the cascade molecules, it is apparent that cells will not be able to adhere properly and will eventually undergo apoptosis, as we have found with cells grown on Vn in the presence of HKa. HKa can directly bind to Mac-1 integrin found in leukocytes, thus blocking adhesion of HEK293 cells to fibrinogen and ICAM-1.42 Therefore, HKa may potentially disrupt integrin-mediated adhesion in a similar manner through its direct association with certain integrins present in endothelial cells. It was recently reported that the apoptotic activity of HKa may be mediated through its interaction with tropomyosin.43 Apparently, the interaction between HKa and cell surface proteins is highly complex.

Tarui et al demonstrated that integrin {alpha}5ß1 is pivotal to the signal transduction of uPAR.44 Together with the evidence that uPAR binds integrin with high affinity and facilitate integrins’ function in cell adhesion and migration as discussed in this study, dissociation of uPAR from integrins diminishes these signaling events. Thus, by providing evidence that anti-uPAR antibodies blocked the apoptotic effect of HKa and HKa mediated dissociation of uPAR-integrin, the present study provides a mechanistic explanation of HKa-induced human endothelial cell apoptosis.


*    Acknowledgments
 
This study was supported by R01 CA63938 (R.W.C.) and a grant from the American Heart Association 0265404U (Y.-L.G.). Dian J. Cao is a recipient of a postdoctoral fellowship supported by NIH Training Grant T32 HL 07777 (R.W.C.).


*    Footnotes
 
Original received December 3, 2003; resubmission received January 29, 2004; revised resubmission received March 16, 2004; accepted March 16, 2004.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 

  1. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med. 1995; 1: 120–122.[Medline] [Order article via Infotrieve]
  2. Beckner ME. Factors promoting tumor angiogenesis. Cancer Invest. 1999; 17: 594–623.[Medline] [Order article via Infotrieve]
  3. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem. 2000; 275: 1521–1524.[Free Full Text]
  4. Cao Y, Chen A, An SSA, Ji RW, Davidson D, Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem. 1997; 272: 22924–22928.[Abstract/Free Full Text]
  5. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88: 277–285.[CrossRef][Medline] [Order article via Infotrieve]
  6. Colman RW. Biologic activities of the contact factors in vivo–potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis. Thromb Haemost. 1999; 82: 1568–1577.[Medline] [Order article via Infotrieve]
  7. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997; 90: 3819–3843.[Free Full Text]
  8. Asakura S, Hurley RW, Skorstengaard K, Ohkubo I, Mosher DF. Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol. 1992; 116: 465–476.[Abstract/Free Full Text]
  9. Weisel JW, Nagaswami C, Woodhead JL, DeLa Cadena RA, Page JD, Colman RW. The shape of high molecular weight kininogen: organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J Biol Chem. 1994; 269: 10100–10106.[Abstract/Free Full Text]
  10. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000; 95: 543–550.[Abstract/Free Full Text]
  11. Zhang JC, Claffey K, Sakthivel R, Darzynkiewicz Z, Shaw DE, Leal J, Wang YC, Lu FM, McCrae KR. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J. 2000; 14: 2589–2600.[Abstract/Free Full Text]
  12. Parenti A, Morbidelli L, Ledda F, Granger HJ, Ziche M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 2001; 15: 1487–1489.[Free Full Text]
  13. Colman RW, Pixley RA, Sainz IM, Song JS, Isordia-Salas I, Muhamed SN, Powell JA, Mousa SA. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J Thromb Haemost. 2003; 1: 164–170.[CrossRef][Medline] [Order article via Infotrieve]
  14. Guo YL, Wang S, Colman RW. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol. 2001; 21: 1427–1433.[Abstract/Free Full Text]
  15. Wang S, Hasham MG, Isordia-Salas I, Tsygankov AY, Colman RW, Guo YL. Regulation of cardiovascular signaling by kinins and products of similar converting enzyme systems: upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen. Am J Physiol Heart Circ Physiol. 2003; 284: H1917–H1923.[Abstract/Free Full Text]
  16. Guo YL, Wang S, Cao DJ, Colman RW. Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. J Cell Biochem. 2003; 89: 622–632.[CrossRef][Medline] [Order article via Infotrieve]
  17. Al-Fakhri N, Chavakis T, Schmidt-Woll T, Huang B, Cherian SM, Bobryshev YV, Lord RS, Katz N, Preissner KT. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol Chem. 2003; 384: 423–435.[CrossRef][Medline] [Order article via Infotrieve]
  18. Aguirre Ghiso JA, Alonso DF, Farias EF, Gomez DE, Kier Joffe EB. Deregulation of the signaling pathways controlling urokinase production: its relationship with the invasive phenotype. Eur J Biochem. 1999; 263: 295–304.[Medline] [Order article via Infotrieve]
  19. Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, McCrae KR. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest. 1997; 100: 1481–1487.[Medline] [Order article via Infotrieve]
  20. Guo YL, Kang B, Yang LJ, Williamson JR. Tumor necrosis factor-{alpha} and ceramide induce cell death through different mechanisms in rat mesangial cells. Am J Physiol. 1999; 276: F390–F397.[Medline] [Order article via Infotrieve]
  21. Wei Y, Eble JA, Wang Z, Kreidberg JA, Chapman HA. Urokinase receptors promote ß1 integrin function through interactions with integrin {alpha}3ß1. Mol Biol Cell. 2001; 12: 2975–2986.[Abstract/Free Full Text]
  22. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science. 1996; 273: 1551–1555.[Abstract]
  23. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol. 1999; 144: 1285–1294.[Abstract/Free Full Text]
  24. Li S, Couet J, Lisanti MP. Src tyrosine kinases, G{alpha} subunits, and H-ras share a common membrane-anchored scaffolding protein, caveolin. caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem. 1996; 271: 29182–29190.[Abstract/Free Full Text]
  25. Li L, Okura M, Imamoto A. Focal adhesions require catalytic activity of Src family kinases to mediate integrin-matrix adhesion. Mol Cell Biol. 2002; 22: 1203–1217.[Abstract/Free Full Text]
  26. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994; 269: 32380–32388.[Abstract/Free Full Text]
  27. Chavakis T, Kanse SM, Lupu F, Hammes HP, Muller-Esterl W, Pixley RA, Colman RW, Preissner KT. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood. 2000; 96: 514–522.[Abstract/Free Full Text]
  28. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res. 1996; 224: 344–353.[CrossRef][Medline] [Order article via Infotrieve]
  29. Kjoller L, Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol. 2001; 152: 1145–1157.[Abstract/Free Full Text]
  30. Joseph K, Ghebrehiwet B, Kaplan AP. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin Immunol. 1999; 92: 246–255.[CrossRef][Medline] [Order article via Infotrieve]
  31. Hasan AAK, Zisman T, Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci U S A. 1998; 95: 3615–3620.[Abstract/Free Full Text]
  32. Joseph K, Tholanikunnel BG, Ghebrehiwet B, Kaplan AP. Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb Haemost. 2004; 91: 61–70.[Medline] [Order article via Infotrieve]
  33. Mahdi F, Shariat-Madar Z, Todd RF III, Figueroa CD, Schmaier AH. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood. 2001; 97: 2342–2350.[Abstract/Free Full Text]
  34. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol. 2000; 12: 621–628.[CrossRef][Medline] [Order article via Infotrieve]
  35. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, Vassalli JD. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol. 1993; 122: 673–684.[Abstract/Free Full Text]
  36. Preissner KT, Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res. 1998; 89: 1–21.[CrossRef][Medline] [Order article via Infotrieve]
  37. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol. 1997; 9: 714–724.[CrossRef][Medline] [Order article via Infotrieve]
  38. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem. 2000; 275: 21785–21788.[Free Full Text]
  39. Simon KO, Nutt EM, Abraham DG, Rodan GA, Duong LT. The {alpha}vß3 integrin regulates {alpha}5ß1-mediated cell migration toward fibronectin. J Biol Chem. 1997; 272: 29380–29389.[Abstract/Free Full Text]
  40. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol. 1996; 134: 793–799.[Abstract/Free Full Text]
  41. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol. 2001; 13: 555–562.[CrossRef][Medline] [Order article via Infotrieve]
  42. Sheng N, Fairbanks MB, Heinrikson RL, Canziani G, Chaiken IM, Mosser DM, Zhang H, Colman RW. Cleaved high molecular weight kininogen binds directly to the integrin CD11b/CD18 (Mac-1) and blocks adhesion to fibrinogen and ICAM-1. Blood. 2000; 95: 3788–3795.[Abstract/Free Full Text]
  43. Zhang JC, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP, Pang YP, McCrae KR. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci U S A. 2002; 99: 12224–12229.[Abstract/Free Full Text]
  44. Tarui T, Andronicos N, Czekay RP, Mazar AP, Bdeir K, Parry GC, Kuo A, Loskutoff DJ, Cines DB, Takada Y. Critical role of integrin {alpha}5ß1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem. 2003; 278: 29863–29872.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Y. Wu, V. Rizzo, Y. Liu, I. M. Sainz, N. G. Schmuckler, and R. W. Colman
Kininostatin Associates With Membrane Rafts and Inhibits {alpha}v{beta}3 Integrin Activation in Human Umbilical Vein Endothelial Cells
Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1968 - 1975.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. M. Khan, H. N. Bradford, I. Isordia-Salas, Y. Liu, Y. Wu, R. G. Espinola, B. Ghebrehiwet, and R. W. Colman
High-Molecular-Weight Kininogen Fragments Stimulate the Secretion of Cytokines and Chemokines Through uPAR, Mac-1, and gC1qR in Monocytes
Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2260 - 2266.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Sun and K. R. McCrae
Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species
Blood, June 15, 2006; 107(12): 4714 - 4720.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
94/9/1227    most recent
01.RES.0000126567.75232.46v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cao, D. J.
Right arrow Articles by Colman, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cao, D. J.
Right arrow Articles by Colman, R. W.
Related Collections
Right arrow Other Vascular biology
Right arrow Angiogenesis
Right arrow Apoptosis